Citius Pharmaceuticals Inc. (NASDAQ: CTXR)
$2.7000
+0.1000 ( +4.25% ) 66.1K
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Market Data
Open
$2.7000
Previous close
$2.6000
Volume
66.1K
Market cap
$20.94M
Day range
$2.5750 - $2.8600
52 week range
$2.4400 - $26.7500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | Sep 05, 2024 |
4 | Insider transactions | 1 | Aug 30, 2024 |
4 | Insider transactions | 1 | Aug 30, 2024 |
8-k | 8K-related | 19 | Aug 16, 2024 |
8-k | 8K-related | 15 | Aug 12, 2024 |
10-q | Quarterly Reports | 58 | Aug 12, 2024 |
8-k | 8K-related | 16 | Aug 08, 2024 |
8-k | 8K-related | 15 | May 21, 2024 |
8-k | 8K-related | 15 | May 14, 2024 |
10-q | Quarterly Reports | 55 | May 14, 2024 |